Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 278-636-5 | CAS number: 77182-82-2
Endpoint summary
Administrative data
Description of key information
There are several case reports available in literature. However, these reported cases mainly refer to acute poisoning with the formulated products, not with the active ingredient (GA) itself. In poisonings with products containing Glufosinate ammonium the surfactants in the formulation, as well as the other ingredients, may play an important role for some of the symptoms observed.
The main findings of these reports are summarized as follows:
Human poisoning cases resulted in nausea, vomiting, diarrhea, abdominal pain, tremor, hypotension, bradycardia or tachycardia, muscle weakness, drowsiness, loss of consciousness and coma, convulsions, and respiratory arrest. Rarely hyperthermia has been described, as has in one case of ingestion of a very high dose diabetes insipidus, and in one case double vision and nystagmus due to palsy of the 6th cranial nerve. Retro- and anterograde amnesia and memory deficits can occur. The fatality rate in reported poisonings is about 18%. The neurological symptoms may suddenly appear with a delay (latency period) of 8 to 48 hours
without warning. Both cytotoxic and vasogenic edema have been reported in brain regions.
Additional information
Based on the effects on the human central nervous system reported after single exposures to GA formulations and based on the fact that these effects have also been reported in animals exposed to the pure substance, glufosinate ammonium is classified for target organ toxicity (central nervous system) in accordance with Regulation (EC) 1272/2008 (STOT SE Cat.1; H370).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
